



**HAL**  
open science

## **Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer.**

Guillaume Ploussard, Laurent J. Salomon, Yves Allory, Stéphane Terry, Dimitri Vordos, Andreas Hoznek, Claude-Clément Abbou, Francis Vacherot, Alexandre de La Taille

### ► To cite this version:

Guillaume Ploussard, Laurent J. Salomon, Yves Allory, Stéphane Terry, Dimitri Vordos, et al.. Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer.. *BJU International*, 2010, 106 (1), pp.86-90. 10.1111/j.1464-410X.2009.09080.x . inserm-00502462

**HAL Id: inserm-00502462**

**<https://inserm.hal.science/inserm-00502462>**

Submitted on 22 Nov 2010

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Pathological findings and PSA outcomes after laparoscopic radical**  
2 **prostatectomy for high risk prostate cancer**

3  
4 Guillaume Ploussard, Laurent Salomon, Yves Allory, Stéphane Terry, Dimitri Vordos,  
5 Andreas Hoznek,  
6 Claude-Clément Abbou, Francis Vacherot, Alexandre de la Taille  
7 INSERM U955 EQ07, Departments of Urology and Pathology, APHP,  
8 CHU Henri Mondor,  
9 Créteil, France

10  
11 Correspondence:

12 Dr A. de la Taille

13 INSERM U955 Eq07 Department of Urology

14 CHU Mondor

15 51, avenue du Maréchal de Lattre de Tassigny

16 94000 Créteil, France

17 Tel: 33149812254

18 Fax: 33149812568

19 Email: adelataille@hotmail.com

20  
21 Keywords : prostate cancer ; high risk ; radical prostatectomy ; biochemical  
22 recurrence

27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

## ABSTRACT

*Objective:* The aim of our study was to review the biochemical recurrence-free survival (RFS) rates of laparoscopic radical prostatectomy (RP) in patients with high risk of disease progression as defined by preoperative d'Amico criteria.

*Patients and Methods:* Between October 2000 and May 2008, 110 patients underwent extraperitoneal laparoscopic radical prostatectomy and bilateral pelvic lymph node sampling for high risk prostate cancer in our department. High-risk prostate cancer was defined as follows: a PSA level greater than 20ng/ml, and/or a biopsy Gleason score 8 or above, and/or a clinical AJCC T2c to T4 stage. Median follow-up was 37.6 months. Risk factors for time to biochemical recurrence were tested using log rank survivorship analysis and Cox proportional hazards regression.

*Results:* Prostate cancer was organ-confined in 35.5% of cases. Overall RFS was 79.4% and 69.8% at 1 and 3 years, respectively. The 3-year RFS rates for organ-confined cancer versus extracapsular extension were 100% and 54.3%, respectively ( $p<0.001$ ). The 3-year RFS rates for tumor-free seminal vesicle versus seminal vesicle invasion were 81.8% and 33.6%, respectively ( $p<0.001$ ). The 3-year RFS rates for negative surgical margins versus positive were 85.2% and 47.3%, respectively ( $p=0.001$ ). Compared with men with any single pathological risk factor or any 2 risk factors, men with all 3 risk factors had significantly shorter time to PSA failure after RP (log-rank test:  $p<0.001$ ).

52            *Conclusion:* Among patients at increased risk of disease progression as defined by  
53            preoperative d'Amico criteria, a third of men with organ-confined disease have  
54            favorable prognosis. Men at high risk for early PSA failure could be better identified  
55            by pathological assessment on prostatectomy specimens, and selected for phase III  
56            randomized trials investigating adjuvant systemic treatment.

57

58 INTRODUCTION

59

60 Prostate cancer is the most common solid malignancy in men in EU, with 186,320  
61 new cases diagnosed each year and the second cause of death attributable to cancer  
62 with 28,660 deaths per year [1]. Despite the widespread use of prostate-specific  
63 antigen (PSA) screening some patients are diagnosed with a locally advanced prostate  
64 cancer. In these cases, treatment options remains unclear with no clear consensus.  
65 D'Amico et al proposed a useful classification using clinical and pathological  
66 parameters to classify relapse risk before treatment [2]. Patients with a PSA >20 ng/  
67 mL, Gleason 8-10, T2c to T4 disease are considered to be at high risk, with recurrence  
68 rates ranged from 50 to 100 percent after a local therapy alone especially if they are  
69 young, healthy and with a long life expectancy. A nomogram from the Memorial  
70 Sloan-Kettering Center has also been validated to predict biochemical recurrence-free  
71 survival (RFS) after radical prostatectomy (RP) [3]. For patients with organ-confined  
72 and high risk of disease progression prostate cancer, external beam radiation therapy  
73 and RP are two recommended treatment options. One important advantage for RP is  
74 that cancer aggressiveness is correctly evaluated on RP specimen. Thus, postoperative  
75 nomograms can be used to better characterize high risk patients and predict the  
76 probability of prostate cancer recurrence for each patient [4]. Pathological risk factors  
77 for disease recurrence and disease specific survival after radical prostatectomy (RP)  
78 include extracapsular extension, high Gleason score, positive surgical margins,  
79 seminal vesicle invasion and positive lymph nodes [5]. Despite treatment, a significant  
80 proportion of these patients will experience PSA-defined failure and cancer-specific  
81 death indicating a need for more aggressive initial therapy. However, no adjuvant  
82 standard treatment after surgery is clearly recommended for high risk and locally

83 advanced tumors. Immediate adjuvant radiotherapy decreased the risk of PSA  
84 recurrence but at the cost of increased toxicity and with no metastasis-free or overall  
85 survival benefit [6,7]. Adjuvant hormone therapy significantly improves survival in  
86 patients with positive lymph nodes with benefit for immediate therapy [8,9]. In case of  
87 negative lymph nodes, this survival advantage is not demonstrated. Recently,  
88 neoadjuvant or adjuvant therapy for patients with high risk prostate cancer was studied  
89 and demonstrated feasible with acceptable toxicity [10,11,12]. Therefore, stratifying  
90 patients according to the prognosis is important for postoperative counseling and the  
91 consideration of adjuvant therapy.

92 The purpose of the current study was to estimate the biochemical outcome after  
93 laparoscopic RP for high risk of disease progression prostate cancer and to investigate  
94 whether the number of pathological risk factor on prostatectomy specimens is  
95 significantly associated with the time to PSA failure.

96

## MATERIALS AND METHODS

97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121

Study population.

Between October 2000 and May 2008, 110 patients underwent extraperitoneal laparoscopic radical prostatectomy and bilateral pelvic lymph node sampling for high risk prostate cancer in our department. High risk cancers were defined as follows: a PSA level greater than 20 ng/mL, and/or a Gleason score of  $\geq 8-10$ , and/or clinical T2c to T4 disease regarding d'Amico criteria [2]. The patients have negative bone scan and negative computed tomography (CT) scan. Baseline and follow-up information were collected prospectively in our database including preoperative clinical and biological characteristics, patient demographics, surgical data and postoperative parameters. The clinical stage was determined from the digital rectal examination findings according to the AJCC staging system. A standard pelvic lymph node dissection (external iliac artery area) was performed in all patients. A mean of 7.4 lymph nodes were sampled. Nerve-sparing surgery was performed in 34 patients (30.9%). Pathological Gleason score, surgical margin (SM) status, presence of extracapsular extension (ECE), seminal vesicle invasion (SVI) and pelvic lymph node positivity were recorded. All prostatectomy specimens were assessed by a referee genitourinary pathologist. Biochemical recurrence was defined as any detectable serum PSA (greater than 0.2 ng/ml). Patients who had pelvic lymph nodes metastases received immediate androgen deprivation therapy. Others patients who received adjuvant or neoadjuvant hormonal and/or radiation therapy before PSA failure which was the primary end point in this study, were excluded from analyses. Men who experienced PSA failure were managed according to standard practice. Table 1 lists the preoperative characteristics of the 110 patients. Patients were classified at higher

122 risk of disease progression on PSA level alone in 61 patients (55.5%), on high  
123 Gleason score alone in 31 patients (28.2%), on combination of these two parameters  
124 in 9 patients (8.2%) and on clinical AJCC stage alone in 9 patients (8.2%). The mean  
125 and median follow-up for all patients was 38.1 and 37.6 months, respectively (range:  
126 1.1-92.2). The frequency of follow-up visits was standardized for all patients.

#### 127 128 Statistical analysis.

129 Preoperative clinico-biological parameters were studied according to time-to-PSA  
130 failure. We used dichotomized values of preoperative PSA (20 or less versus greater  
131 than 20ng/ml), prostate weight (30 or less versus greater than 30ml) and age (<60  
132 versus >60 years old). A Cox proportional hazards regression was used.

133 For purpose of illustration, estimates of PSA outcomes were calculated using the  
134 Kaplan-Meier actuarial method and graphically displayed. PSA failure was defined by  
135 a PSA level > 0.2 mg/ml. The time to PSA failure was considered to be the time that  
136 the first detectable value was measured. The day of surgery was reported as the  
137 starting point of analysis. The analysis endpoint was biochemical recurrence-free  
138 survival (RFS). Postoperative significant risk factors for time to biochemical  
139 recurrence were examined using log rank survivorship analysis. All data were  
140 analyzed using SPSS 13.0 software (Chicago, Illinois). The limit of statistical  
141 significance was defined as  $p < 0.05$ .



145 RESULTS

146

147

148 *Pathological parameters on prostatectomy specimens (see Table2)*

149 Of the 110 patients undergoing RP, the pathological findings were extracapsular  
150 extension (ECE) in 71 (64.5%), seminal vesicle involvement (SVI) in 27 (24.5%),  
151 positive surgical margin (R+) in 43 (39.1%) and pelvic lymph node metastases (N+)  
152 in 4 (3.6%). Surgical margins were positive in 21.0%, 27.3%, 61.1% and 71.4% of  
153 pT2, pT3a, pT3b and pT4 cancers, respectively.

154 Concordance between biopsy and postprostatectomy Gleason scores was 49.1%.

155 Biopsy upgraded pathological Gleason score in 16 patients (14.5%) and downgraded it  
156 in 40 patients (36.4%). The rate of favourable disease (defined as pT2 cancer and a  
157 Gleason score  $\leq 7$ ) on RP specimens was 26.4%. Only 7 patients (6.4%) fulfilled all  
158 favourable criteria, i.e. a PSA < 20 mg/ml, a pT2 cancer and a Gleason score  $\leq 7$  on RP  
159 specimen.

160

161 *Time to PSA failure analyses*

162 During a mean follow-up of 38.1 months, PSA failure occurred in 23 patients (20.9%)  
163 of which 20 received salvage therapy (radiotherapy or hormonal therapy). Fourteen  
164 patients were treated by radiotherapy and 6 men received androgen deprivation  
165 therapy. Mean time to progression was 7.2 months. No patient died as a result of  
166 prostate cancer before PSA failure.

167 Multivariate time-to-failure analysis on preoperative parameters showed PSA level  
168 higher than 20 ng/mL (p=0.003; HR=7.14 [95% CI 1.93-26.3]) and high biopsy  
169 Gleason score (p=0.023; HR=3.14 [95% CI 1.17-8.43]) to be independent predictors

170 of biochemical recurrence. Age ( $p=0.658$ ; HR=0.82 [95% CI 0.34-1.95]), clinical  
171 stage ( $p=0.362$ ; HR=1.49 [95% CI 0.63-3.48]) and prostate weight ( $p=0.530$ ;  
172 HR=0.62 [95% CI 0.14-2.75]) were not significantly associated with biochemical  
173 relapse.

174 Overall RFS was 79.4% at 1 year (95% confidence interval [CI]: 75.1-83.7%) and  
175 69.8% at 3 years (95% CI 63.9-75.7%) (Figure 1).

176

#### 177 *PSA failure stratified by pathological data (Figure 2)*

178 The 3-year RFS rates for organ-confined cancer versus extracapsular extension were  
179 100% and 54.3% (95% CI 46.3-62.3%), respectively ( $p<0.001$ ). The 3-year RFS rates  
180 for tumor-free seminal vesicle versus seminal vesicle invasion were 81.8% (95% CI  
181 76.1-87.5%) and 33.6% (95% CI 20.4-46.8%), respectively ( $p<0.001$ ). The 3-year  
182 RFS rates for negative surgical margins versus R+ were 85.2% (95% CI 79.4-91.0%)  
183 and 47.3% (95% CI 36.9-57.7%), respectively ( $p=0.001$ ).

184 The estimated rates of RFS stratified by the number of pathological risk factors  
185 present are illustrated in Figure 3. When these 3 pathological factors were associated  
186 (SVI, R+, ECE), the 1-year and 3-year RFS rates were 42.2% (95% CI 29.5-54.9%)  
187 and 15.8% (95% CI 2.8-28.8%). Statistically significant difference appeared  
188 according to the number of these factors present (log-rank test:  $p<0.001$ ).

189 None of the 9 patients with pT2 cancer and positive margin developed PSA  
190 recurrence. Comparatively, the 1-year and 3-year RFS rates were 84% and 74.7% in  
191 patients with pT3 cancer and negative margin. Difference did not reach significance  
192 (log-rank test:  $p=0.185$ ).

193 DISCUSSION

194  
195 An accurate prediction of probability of disease recurrence is essential for proper  
196 patient selection. Preoperatively, the identification of high risk prostate cancer can be  
197 based on, at least, three well-defined predictors of the disease extent and outcome  
198 after treatment: AJCC clinical T stage, serum PSA level, and Gleason score. Patients  
199 with AJCC clinical stage T2c-T4 disease and/or a PSA level of more than 20ng/mL  
200 and/or a biopsy Gleason score of 8 or more have a risk higher than 50% at 5 years of  
201 post-treatment PSA failure. This risk group was established from a review of literature  
202 and well defined by d'Amico et al. studying PSA failure and prostate cancer-specific  
203 mortality [2,13]. In addition, PSA velocity greater than  $>2$  ng/mL/year and more than  
204 50% of positive biopsies can be considered [14,15]. D'Amico et al reported in a study  
205 including 1,095 patients who underwent RP and who did not receive adjuvant therapy  
206 that on multivariable analysis, preoperative PSA velocity  $>2$ ng/mL/year was  
207 associated with an increased risk of cancer specific mortality and with an increased  
208 risk of overall mortality [16]. Others preoperative nomograms or scores have been  
209 developed and validated in internal and external studies, documenting a high level of  
210 consistency [3,17]. However, despite a good predictive accuracy among different risk  
211 groups, certain inconsistencies have been reported regarding high risk cases. In the  
212 present series we studied PSA-defined follow-up and results of local therapy for  
213 patients at high risk of cancer progression regarding preoperative d'Amico criteria [2].  
214 Survival analyses were driven in order to identify different risk subgroups of PSA  
215 failure according to final pathological assessment among patients suspicious for high  
216 risk of biochemical failure.

218 In multivariate time-to-failure analysis, high biopsy Gleason score and serum PSA  
219 were significantly associated with biochemical relapse in our cohort. Preoperative  
220 PSA greater than 20ng/ml and a Gleason score 8 or above carried a 7.14 and 3.14-time  
221 increased risk of recurrence, respectively. No other preoperative variables were  
222 significantly associated with time to PSA failure. However, we did not study PSA  
223 velocity in this series [16]. Interestingly, clinical AJCC stage did not appear as  
224 significant predictor of biochemical recurrence in this subgroup of high-risk prostate  
225 cancer, on the contrary of published data concerning low-risk and intermediate-risk  
226 group [2,13]. Kupelian et al have already shown that clinical stage was not  
227 independent predictor of PSA-defined failure in a population of patients with biopsy  
228 Gleason score 8 or above [18]. Our data confirmed these results.

229  
230 Biochemical control rates were encouraging for these high risk patients. A third of  
231 these patients have prolonged disease-free survival. Among the 110 patients, prostate  
232 cancer was organ-confined in 35.5% of cases on final pathological assessment.

233 Biochemical RFS was excellent for this subgroup with no cases of recurrence after a  
234 mean follow-up of 37.1 months ( $\pm 23.2$ ). No early PSA failure appeared in case of  
235 organ-confined disease. Moreover, no patient with pT2 cancer and positive surgical  
236 margin had PSA failure. Thus, the biology of organ-confined disease appeared  
237 different compared with the behavior of pT3 cancers. In this series of high-risk PCa,  
238 patients with pT3 cancers and negative surgical margins had poorer survival than  
239 those with pT2 cancer and positive margin (74.7% versus 100% at 3 years after the  
240 surgery). However, difference failed to show significance.

241 In case of biochemical recurrence, patients with positive surgical margins were  
242 preferentially treated by salvage radiotherapy, whereas patients with non organ-

243 confined disease or early PSA failure received preferentially androgen deprivation  
244 therapy.

245 As expected, seminal vesicle invasion and positive surgical margins were statistically  
246 strong predictors of early biochemical recurrence [19]. The 3-year RFS rates for  
247 tumor-free seminal vesicle versus seminal vesicle invasion were 81.8% and 33.6%,  
248 respectively ( $p < 0.001$ ). The 3-year RFS rates for negative surgical margins versus R+  
249 were 85.2% (95% CI 79.4-91.0%) and 47.3% (95% CI 36.9-57.7%), respectively  
250 ( $p = 0.001$ ). The biochemical recurrence in patients with 3 combined pathological  
251 adverse factors was extremely frequent and early with a 3-year RFS of 15.8%.

252 Therefore, men at high risk for early PSA failure could be identified on the basis this  
253 pathological assessment. Not all patients with ECE, positive surgical margins or VSI  
254 will fail biochemically postoperatively, but combination of these 3 parameters was  
255 reported to be a strong predictor of early PSA failure. Compared with men with any  
256 single pathological risk factor or any 2 risk factors, men with all 3 risk factors had  
257 significantly shorter time to PSA failure after RP (log-rank test:  $p < 0.001$ ). However,  
258 the overall risk of relapse may be underestimated in spite of the relative short follow-  
259 up of our cohort. The PCa progresses slowly and a median follow-up of 3 years may  
260 be considered as insufficient.

261  
262 Despite the independent statistical significance of two preoperative clinico-biological  
263 parameters (PSA level and high Gleason score) to predict time to postoperative PSA  
264 failure, most of the variation in PSA follow-up was not accounted for on the basis of  
265 the d'Amico criteria. For patients with organ-confined disease, the outcomes were  
266 remarkably good with RP. Pathological criteria explained a significant amount of the  
267 variation in the postoperative PSA data. Longer follow-up including more patients in

268 the higher risk categories would provide stronger conclusions. One reason of the good  
269 cure rates might be that PSA failure was defined by a PSA level over 0.2 mg/ml  
270 whereas in other series a “0.2 or greater” or a “0.1” cut-off was used [20]. The use of  
271 such a cut-off might be too high when a 3-year RFS is studied and might have limited  
272 detection. We’d also like to emphasize that the biochemical recurrence but not the  
273 prostate cancer specific mortality has been chosen as criteria of disease progression.  
274 The ideal end point on which to make treatment decisions is survival and PSA-defined  
275 failure may not accurately reflect the likelihood of prostate cancer-specific death.  
276 However, early PSA failure is established to be associated with an increased risk of  
277 progression to metastatic disease and prostate cancer-specific death [21].  
278 If longer follow-up and rates of specific mortality confirm these results, adjuvant  
279 therapy might not be mandatory for achieving adequate cure rates for the subgroup of  
280 patients with organ-confined disease. On the contrary, men with two or three  
281 pathological risk factors should be considered for phase III randomized trials  
282 investigating adjuvant systemic treatment. Integrate taxane-based chemotherapy with  
283 local treatment could be relevant to address microscopic hormone-refractory prostate  
284 cancer cells that may be present at initial assessment in men with high-risk disease  
285 [10,11,12].  
286 One limitation of our study is the bias due to the selection of men candidates for RP.  
287 During the study period, 97 others patients have been diagnosed with localized PCa at  
288 high risk of recurrence according to the d’Amico criteria. These patients have been  
289 treated by radiotherapy in 40 cases and by androgen deprivation therapy in 57 elderly  
290 patients. We excluded 47 patients who have been included into a prospective trial  
291 investigating the role of adjuvant paclitaxel after RP. Adjuvant radiotherapy is not

292 performed for high risk PCa before PSA failure at our department and no patient has  
293 received neoadjuvant therapy during the study period.

294 Our findings supported evidence that organ-confined disease, even in preoperatively  
295 high risk patients can lead to excellent RFS outcomes after RP without adjuvant  
296 therapy. Local therapy such as RP has to remain a standard of care for these high risk  
297 patients. Pathological evaluation on prostatectomy specimens provides better  
298 predictive assessment of high risk compared with only preoperative criteria. Despite  
299 high accuracy and mandatory use for selecting men for clinical trials, high risk group  
300 established according to the d'Amico criteria remains heterogeneous, including a third  
301 of patients with excellent prognosis. Radical prostatectomy can help to distinguish  
302 patients who would benefit from adjuvant therapy and close surveillance, from those  
303 who could be watched in a more spaced out way.

304 Finally, this series confirms that laparoscopic approach is a validated treatment of  
305 clinically localized but high-risk disease. Oncological results and positive surgical  
306 margins rates were in line with values published in open surgery series [22,23].

307

308

## CONCLUSIONS

309  
310  
311  
312  
313  
314  
315  
316  
317  
318

Three years after laparoscopic radical prostatectomy for high risk prostate cancer, biochemical recurrence-free survival is 69.8%. Our findings support evidence that organ-confined disease, even in preoperatively high risk patients can lead to excellent RFS outcomes after RP without adjuvant therapy. Among these patients with high risk disease defined by preoperative data, a third of men with organ-confined disease have favorable prognosis. Thus, men at high risk for early PSA failure could be better identified by pathological assessment on prostatectomy specimens, and selected for phase III randomized trials investigating adjuvant systemic treatment.



319 REFERENCES

320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343

[1] Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96

[2] D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.

[3] Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90:766-71.

[4] Kattan MW, Wheeler TM and Scardino PT. Postoperative nomogram for disease recurrence after prostatectomy for prostate cancer. J Clin Oncol 1999; 17:1499-1507.

[5] Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004; 172: 910-914.

[6] Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296:2329-35.

344 [7] Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al.  
345 European Organization for Research and Treatment of Cancer. Postoperative  
346 radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial  
347 22911). *Lancet* 2005 13-19; 366:572-8.

348

349 [8] Messing E M, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D.  
350 Immediate hormonal therapy compared with observation after radical prostatectomy  
351 and pelvic lymphadenectomy in men with node-positive prostate cancer. *N Engl J*  
352 *Med* 1999; 341: 1781-1788.

353

354 [9] Messing E M, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al.  
355 Immediate versus deferred androgen deprivation treatment in patients with node-  
356 positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.  
357 *Lancet Oncol* 2006; 7: 472-479.

358

359 [10] Kibel A S, Rosenbaum E, Kattan M W, Picus J, Dreicer R, Klein EA, et al.  
360 Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical  
361 prostatectomy: a multi-institutional pilot study. *J Urol* 2007; 177: 1777-1781.

362

363 [11] Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE, et al.  
364 Neoadjuvant therapy followed by prostatectomy for clinically localized prostate  
365 cancer. *Cancer* 2007; 110:2628-39.

366

367 [12] Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J, et al.  
368 Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally  
369 advanced prostate cancer. *Urology* 2004; 63:1138-42.

370  
371 [13] Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV. Cancer-  
372 specific mortality after radiation therapy with short-course hormonal therapy or  
373 radical prostatectomy in men with localized, intermediate-risk to high-risk prostate  
374 cancer. *Cancer* 2006; 107:2597-603.

375 [14] Freedland S J, Humphreys E B, Mangold L A, Eisenberger M, Dorey FJ, Walsh  
376 PC,  
377 et al. Risk of prostate cancer-specific mortality following biochemical recurrence after  
378 radical prostatectomy. *JAMA* 2005; 294: 433-439.

379  
380 [15] Ravery V, Chastang C, Toubanc M, Boccon-Gibod L, Delmas V, Boccon-Gibod  
381 L. Percentage of cancer on biopsy cores accurately predicts extracapsular extension  
382 and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer. *Eur*  
383 *Urol* 2000; 37: 449-455.

384  
385 [16] D'Amico A V, Chen M H, Roehl K A, Catalona WJ. Preoperative PSA velocity  
386 and the risk of death from prostate cancer after radical prostatectomy. *N Engl J Med*  
387 2004; 351: 125-135.

388  
389 [17] Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC Jr, Amling CL, et  
390 al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for  
391 prediction of recurrence after radical prostatectomy. *Cancer* 2006; 107:2384-91.

392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415

[18] Kupelian PA, Buchsbaum JC, Elshaikh M, Reddy CA, Zippe C, Klein EA. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. *Cancer* 2002; 95:2302-7.

[19] D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. *J Urol* 1995; 154:131-8.

[20] Pavlovich CP, Trock BJ, Sulman A, Wagner AA, Mettee LZ, Su LM. 3-year actuarial biochemical recurrence-free survival following laparoscopic radical prostatectomy: experience from a tertiary referral center in the United States. *J Urol* 2008;179:917-21

[21] Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. *J Urol* 2006; 176:1404-8.

[22] Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. *J Urol* 1998; 160:2428-34.

416 [23] Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical  
417 disease-free and cancer-specific survival following anatomic radical retropubic  
418 prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;  
419 28:555-65.

420

421

422

LEGENDS

423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442

Table 1. Baseline characteristics of the 110 patient study cohort.

Table 2. Pathological postprostatectomy parameters.

Figure 1. Biochemical recurrence-free survival after RP for high risk prostate cancer.

Figure 2. Biochemical RFS after RP stratified by the type of pathological risk factor present.

Figure 3. Biochemical RFS after RP stratified by the number of pathological risk factors (ECE, VSI, R+).